Ken-Kuo Lin

Dr. Ken-Kuo Lin


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Ophthalmology
Verified
Journal Article
Closed access
PWPei-Chang Wu
Pei-Chang Wu
CCChueh-Tan Chen
Chueh-Tan Chen
KLKen-Kuo Lin
Ken-Kuo Lin
CSChi-Chin Sun
Chi-Chin Sun
CKChien-Neng Kuo
Chien-Neng Kuo
YYYi-Hsin Yang
Yi-Hsin Yang

1 March 2021 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
KLKen-Kuo Lin
Ken-Kuo Lin
JLJiahn-Shing Lee
Jiahn-Shing Lee
CHChiun-Ho Hou
Chiun-Ho Hou
WCWei-Min Chen
Wei-Min Chen
CHChing-Hsi Hsiao
Ching-Hsi Hsiao
LSLai-Chu See
Lai-Chu See

19 July 2016 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
CLChia-Yi Lee
Chia-Yi Lee
CSChi Chin Sun
Chi Chin Sun
YLYi-Fang Lin
Yi-Fang Lin
KLKen-Kuo Lin
Ken-Kuo Lin
Myopia-related maculopathy is one of the leading causes of blindness in the world. The prevalence of myopia has been reported as high as 90 % in some Asian countries. Therefore, controlling myopia progression is an urgent public issue. The purpose of this study is to evaluate the effects of topical atropine with different concentrations on intraocular pressure measurements and myopia progression in school-aged children in Taiwan. Fifty-six myopic children were divided into three groups: 32 children were treated with 0.125 % atropine eyedrop; 12 of them were treated with 0.25 % atropine eye drop and another 12 served as a control group. IOP, auto-refractor and manifest refraction were measured at baseline and every 3 months following treatment for one year. There were no significant differences for the mean age, gender and baseline IOPs among the three groups. During the follow up period, no significant IOP difference was found among three groups. The change between final and baseline mean IOPs also revealed no significant differences: 0.54 mmHg, −1.28 mmHg, −0.33 mmHg for the 0.125 % atropine, 0.25 % atropine and control groups. The baseline mean spherical equivalent similarly did not differ significantly among groups but the control group showed a significant myopic progression compared to the 0.125 % atropine group 6 months after treatment, and persisted for one year. The change between final and baseline mean spherical equivalents were −0.05 D, 0 D, −1.05 D for the 0.125 % atropine, 0.25 % atropine and control groups, with both atropine-treated groups showing significant myopic retardation compared to the control group. Topical use of low concentration atropine for one year does not induce ocular hypertension and is effective for retarding myopic progression. However, further large scale studies with longer follow up period is necessary to validate the long term safety and efficacy. ISRCTN33002849 , 2016/01/19, retrospectively registered.

1 February 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
JLJiahn-Shing Lee
Jiahn-Shing Lee
PLPei-Ru Li
Pei-Ru Li
CHChiun-Ho Hou
Chiun-Ho Hou
KLKen-Kuo Lin
Ken-Kuo Lin
CKChang-Fu Kuo
Chang-Fu Kuo
LSLai-Chu See
Lai-Chu See

27 April 2022 in Medicina
Verified
Journal Article
Open access
PDF file
JLJiahn-Shing Lee
Jiahn-Shing Lee
KLKen-Kuo Lin
Ken-Kuo Lin
CHChiun-Ho Hou
Chiun-Ho Hou
PLPei-Ru Li
Pei-Ru Li
LSLai-Chu See
Lai-Chu See
Background and Objectives: Subjective visual function is currently becoming an increasing appreciation in assessing the health-related quality of life. This study aimed to assess the vision-related quality of life (VRQOL) among patients with refractive errors, keratoconus, senile cataract, and age-related macular degeneration (AMD) using the Chinese version of the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25). Materials and Methods: The questionnaire of NEI-VFQ-25 was filled out in a clinical setting or by telephone/mail. Univariate and multivariate analyses were used to determine which factors are associated with the NEI-VFQ-25. Results: From June 2018 to January 2019, 28 patients with refractive error, 20 patients with keratoconus, 61 with senile cataracts, and 17 with AMD completed the questionnaire NEI-VFQ-25. There were significant differences in the NEI-VFQ-25 subscale of general vision (p = 0.0017), ocular pain (p = 0.0156), near activities (p = 0.0002), vision-specific social functioning (p = 0.007), vision-specific mental health (p = 0.0083), vision-specific dependency (p = 0.0049), color vision (p < 0.0001), peripheral vision (p = 0.0065), and total score (p < 0.0001) among four disease groups, respectively. The multiple linear regression revealed that the best-corrected visual acuity (BCVA) and disease group were important factors of the total NEI-VFQ-25. After adjusting for BCVA, patients with AMD had a worse total NEI-VFQ-25 score than patients with refractive error, keratoconus, or senile cataracts. Conclusions: Among the patients with four ocular disorders and a broad vision spectrum from normal, partial sight, low vision to legal blindness, the BCVA of their better eye was the most important factor in the VRQOL.

14 February 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
YKYu Kai Kuo
Yu Kai Kuo
YCYEN-TING CHEN
YEN-TING CHEN
HCHo-Min Chen
Ho-Min Chen
PWPei-Chang Wu
Pei-Chang Wu
CSChi-Chin Sun
Chi-Chin Sun
CLChun-Fu Liu
Chun-Fu Liu
The association between myopia control efficacy in children treated with orthokeratology and corneal epithelial thickness is still unknown. The aim of this study was to explore the corneal epithelial thickness and its association with axial length changes in children treated with orthokeratology. This retrospective cohort study enrolled children aged from 9 to 15 years who had received orthokeratology for myopia control and had been followed up for at least 1 year. Anterior segment optical coherence tomography was performed to generate wide epithelial thickness maps of the patients. Annual axial length changes were calculated from the axial length at 6 months after the initiation of orthokeratology lens wear and at final measurements. Corneal epithelial thickness data were obtained from 24 sectors and a central 2 mm zone of the wide epithelial thickness map. Associations between annual axial length changes and corneal epithelial thickness for each sector/zone of the wide epithelial thickness map, and orthokeratology treatment data were determined by generalized estimating equations. Finally, a total of 83 eyes of 43 patients (mean age 11.2 years) were included in the analysis. The mean annual axial length change was 0.169 mm; when regressing demographic and ortho-k parameters to mean annual axial length changes, age and target power were both negatively associated with them (β = −14.43, p = 0.008; β = −0.26, p = 0.008, respectively). After adjusting for age and target power, the annual axial length changes were positively associated with the corneal epithelium thickness of IT1, I1, SN2, and S2 sectors of the wide epithelial thickness map, and negatively with that of the I3 sector. In conclusion, we identified associations between annual axial length changes and the corneal epithelium thickness of certain sectors in children treated with orthokeratology. This may facilitate the design of orthokeratology lenses with enhanced efficacy for myopia control.